What looked like a small fee tweak has turned into a very large workflow conversation.
The United States Patent and Trademark Office’s new Information Disclosure Statement fee framework has changed the tone of patent prosecution in a hurry. On paper, the rule sounds simple enough: if your IDS filings push the cumulative number of applicant-provided references past certain thresholds, you may owe a new size fee. In practice, though, this is not just a pricing update. It is a behavior update, a process update, and for many patent teams, a blood-pressure update.
That is why the new USPTO IDS fee regime has started raising high-stakes questions for applicants, in-house counsel, outside prosecution teams, and the people who must somehow keep family-wide reference tracking from turning into a legal version of laundry day. The issue is not merely whether an applicant might owe $200, $500, or $800. The bigger issue is how these fees interact with the duty of disclosure, timing rules, application families, foreign counterpart citations, examiner efficiency, and the all-too-human tendency to discover a missing checkbox at exactly the worst possible moment.
For patent applicants who operate in reference-heavy industries, the new system is a reminder that patent prosecution is no longer just about drafting strong claims and answering office actions. It is also about information management. And when information management gets expensive, strategic decisions get real very quickly.
What Changed With the New USPTO IDS Fees?
The new rule introduced an IDS size fee structure tied to the cumulative number of applicant-provided or patent owner-provided items submitted during prosecution. The thresholds are straightforward, even if the consequences are not:
- More than 50 items but not more than 100: $200
- More than 100 items but not more than 200: $500, less any amount previously paid
- More than 200 items: $800, less any amount previously paid
That means a filer who crosses the first threshold pays $200. If the same application later crosses 100 references, the filer does not pay a fresh $500 on top of the earlier $200. Instead, the applicant pays the difference needed to bring the total IDS size-fee amount up to $500. If the application later crosses 200 references, the same logic applies until the total paid reaches $800.
Here is the part that really gets practitioners’ attention: unlike many patent fees, these IDS size fees do not receive a small-entity or micro-entity discount. A startup, a university spinoff, and a global conglomerate can all find themselves staring at the same IDS size fee bill. That equal treatment may sound tidy in a spreadsheet, but it lands very differently in real budgets.
The rule also added a new compliance requirement. An IDS filed on or after the effective date must include a clear written assertion stating either that the proper IDS size fee accompanies the filing or that no IDS size fee is due. This sounds minor until you remember how often patent practice runs on forms, routines, docketing habits, and people trying to get five urgent things out the door before lunch.
Why This Is Bigger Than a Simple Fee Increase
The high-stakes part is not the fee alone. It is the combination of new fees, new tracking burdens, and old disclosure obligations. Patent law has always had a special talent for turning “just one more requirement” into a weekend project. This rule keeps that tradition alive.
First, the count is cumulative. The USPTO is not looking only at the size of one individual IDS filing. It is looking at the total number of applicant-provided references over the life of the application. If you file 30 references early, 15 more after a foreign office action, and another 10 later, you have crossed 50. Congratulations. Your patent file has won a fee.
Second, the applicant is responsible for counting. The Office has made clear that patent applicants and patent owners must track the number of items they provide and determine whether a fee is due. In other words, the USPTO is not volunteering to be your IDS accountant. That job stays on your side of the table.
Third, duplicates can count. If the same reference appears more than once in the same application’s IDS history, each listing can count toward the cumulative total. This is one of those details that sounds tiny until you realize how often references move around across foreign reports, attorney reviews, related applications, and resubmissions. In patent practice, duplication is not a bug. It is a lifestyle.
Fourth, the new fee does not replace the old timing-related IDS fee under 37 C.F.R. § 1.17(p). In some circumstances, an applicant can owe both. So now the prosecution team may need to ask two separate questions: is a timing fee due, and is a size fee due? Nothing says “streamlined administration” quite like adding a second fee question to a filing that already had one.
The Compliance Trap Nobody Wants
One reason the patent bar reacted so strongly to the new framework is that the written assertion requirement applies broadly, even though only a minority of applications will ever cross the fee thresholds. If the required assertion is missing, the IDS may be placed in the file but not considered. That sounds procedural, but it can become strategically painful in a hurry.
Imagine the common scenario: an IDS goes in, everyone assumes it is routine, and only later does someone discover that the new assertion language was omitted or the wrong fee bucket was selected. By that point, the application may no longer be in the forgiving stage of prosecution. A harmless-looking paperwork defect can suddenly collide with timing limits, additional fees, or even the need for more substantive prosecution steps. A missing sentence should not become a crisis, but patent procedure occasionally enjoys irony more than it should.
A blanket authorization to charge fees is not enough by itself, either. The written assertion must clearly identify whether a fee is due and which category applies to the specific IDS. This means firms and corporate patent departments cannot rely on autopilot language alone. The process must be intentional, specific, and tied to the filing in question.
Who Feels the Pressure Most?
Not every patent applicant will lose sleep over this rule. The USPTO has indicated that most applications stay below the higher reference counts. But the burden is not evenly distributed, and that is where the policy debate gets interesting.
Applicants in biotech, pharmaceuticals, chemistry, medical devices, advanced materials, and some software fields often work in crowded prior-art environments. They may receive numerous foreign search reports, cite scientific literature, track parallel filings in several jurisdictions, and manage multiple related applications at once. In those areas, a high reference count is not always a sign of sloppy lawyering. Sometimes it is simply the cost of operating in a dense technical landscape.
That reality creates tension. On one hand, the USPTO wants to discourage giant, unfocused IDS dumps that can overwhelm examiners. On the other hand, practitioners know that under-disclosure carries its own risk. When the duty of candor and good faith is sitting in the background, many teams would rather over-disclose than spend years wondering whether a reference left out of the record will come back later with a flamethrower.
So the new IDS size fees do not just raise costs. They sharpen a strategic dilemma: how selective can you be without becoming reckless, and how comprehensive can you be without becoming inefficient?
Examples That Show Why the Rule Matters
Example 1: The startup that did not expect to hit 51
A small patent team files a nonprovisional application and starts with a clean, ordinary-looking record. Then a foreign search report arrives. A few related references are added. A literature search produces several more documents. Individually, each step seems modest. Collectively, the application lands at 55 references. That filing now crosses the first IDS size-fee threshold and triggers a $200 charge, even though nobody on the team ever sat down and said, “Let us make this a large IDS case.”
Example 2: The biotech family with escalating disclosures
A biotech portfolio grows through continuations, office actions, and ongoing publication activity in the field. One application crosses 50 references early and pays $200. Later, new material pushes the count above 100. The application now owes an additional $300, bringing the total to $500. The practical problem is not just the fee. The real problem is that someone must have tracked the count accurately, matched it to the right filing, and made the correct assertion at the right time.
Example 3: The duplicate that was not harmless
A practitioner lists the same journal article twice in different IDS submissions in the same application history. Under the USPTO’s approach, each instance can count. That means poor internal deduplication is no longer just annoying office clutter. It can move an application toward the next fee tier.
Example 4: The continuation that resets some assumptions
Continuations start their own count from zero, which sounds like good news. But if the applicant resubmits references in the child application, those references count in the child. So while the continuation provides a fresh count, it does not magically erase the need for careful citation strategy. It simply gives everyone a fresh opportunity to be organized or chaotic.
Will These Fees Actually Improve Patent Examination?
This is the million-dollar question, which is fitting because every fee debate eventually becomes a philosophy seminar with invoices. The USPTO’s rationale is understandable. Large IDS submissions take examiner time. They can bury relevant art among marginally relevant or cumulative references. If a fee nudges applicants to present cleaner, more focused disclosures, examination could become more efficient.
That is the optimistic view, and it is not crazy. There are certainly cases where a massive IDS looks less like meaningful disclosure and more like a defensive document dump. A structured fee system may push filers to think harder before submitting everything with a pulse.
But critics of the rule have a serious point too. The duty of disclosure does not disappear just because the invoice got sharper. In complex technologies, deciding what is “clearly relevant” versus merely “possibly relevant” can be harder than it sounds, especially when litigation risk is lurking in the distance. If the fee structure nudges applicants toward aggressive filtering, the policy may reduce examiner burden while increasing later arguments over whether something important was left out.
There is also a second concern: a very large IDS does not necessarily protect a patent if the record suggests that the key references were effectively buried. Recent discussion in patent practice has underscored that dumping references into the file is not the same as helping the examiner meaningfully engage with them. So the new rule may push applicants away from quantity, but smart applicants will still need quality, clarity, and judgment.
How Smart Patent Teams Are Responding
Build a real counting system
If your docketing process cannot tell you how many applicant-provided references have already been cited in a given application, you are operating on wishful thinking. The new rule rewards teams that track reference counts continuously rather than reconstructing them in a panic right before filing.
Deduplicate before submission
Because repeat citations can count, firms and legal departments need cleaner workflows for comparing incoming references against what is already in the record. This is not glamorous work, but neither is paying avoidable fees because the same paper keeps showing up like an encore nobody requested.
Coordinate across foreign and domestic teams
Many IDS problems start outside the U.S. application itself. Foreign associates send search results. Related matters generate overlapping references. Internal review happens in stages. A coordinated system for sharing and screening references across jurisdictions can reduce both risk and repetition.
Use updated forms thoughtfully
The USPTO updated its forms, including IDS-related forms such as SB/08 and SB/08c, to help with the new size-fee assertion process. That helps, but forms are not strategy. A checked box only works if the underlying count, fee decision, and timing analysis are correct.
Train people, not just templates
The most dangerous sentence in patent administration is probably, “We have always done it this way.” New rules punish old muscle memory. Paralegals, docketing staff, junior associates, and supervising attorneys all need to know how the IDS size fee works, when it applies, and what happens if the assertion is wrong or missing.
Why the Stakes Feel Especially High Right Now
The patent world is already juggling more than enough: rising prosecution costs, heavier portfolio triage, family-wide filing decisions, global coordination, and increasing pressure to show business value for every legal spend dollar. Against that backdrop, the new IDS size-fee regime lands like one more “small” rule with outsized consequences.
For some applicants, the fee itself will be manageable. For others, especially smaller innovators, it will feel like one more toll booth on the road to protection. But almost everyone in patent prosecution now has to worry about the operational side of compliance. That is why these new Information Disclosure Statement fees raise high-stakes questions. They force applicants to confront a bigger truth: in modern patent practice, information is not just power. It is cost, risk, and strategy all rolled into one.
Experience From the Trenches: What This Topic Feels Like in Real Practice
Anyone who has worked on patent prosecution long enough knows that IDS work rarely arrives at a calm, civilized pace. It shows up in waves. A foreign search report hits the inbox. Then an inventor forwards three articles with the subject line “maybe relevant?” Then another family member gets an office action, which prompts a fresh round of citations everywhere else. Then someone notices that one application is about to allow, and suddenly the entire team is counting references like accountants at tax season with no coffee left.
That is why the new USPTO IDS fees feel so consequential in day-to-day practice. They do not just change what gets paid. They change how people behave under pressure. A paralegal who used to focus mainly on getting the IDS filed now also has to worry about whether the cumulative count is right. A patent attorney who used to say “let us just disclose it to be safe” now has to pause and ask whether the submission is adding truly useful material or merely moving the case closer to the next tier. In-house counsel may suddenly be pulled into questions that used to be treated as routine filing mechanics, because the mechanics now have budget consequences.
There is also a psychological change. Before this rule, a bloated IDS was often viewed as inefficient but survivable. Now it can feel like an avoidable operational mistake, even when the underlying disclosure decision was made in good faith. Teams are becoming more disciplined, but also more cautious. They want better screening, better cross-family communication, and cleaner internal reference libraries. Nobody wants to discover that a duplicate reference counted twice because two offices were working from slightly different spreadsheets that had apparently evolved into separate belief systems.
And then there is the human factor that never shows up cleanly in formal guidance: timing stress. IDS decisions often happen close to deadlines, after long prosecution histories, with imperfect information. That is when details like the written assertion requirement matter most. In theory, it is a simple statement. In practice, it is one more point where a rushed filing can go wrong. The result is that experienced teams are increasingly treating IDS work less like clerical cleanup and more like a managed risk function.
Perhaps the biggest experience-driven lesson is this: the applicants who will handle this rule best are not necessarily the ones with the largest budgets. They are the ones with the cleanest systems. If a team can track references accurately, deduplicate consistently, coordinate across jurisdictions, and make deliberate decisions about what really belongs in the record, the new rule becomes manageable. If not, a modest fee framework can snowball into missed efficiencies, awkward client conversations, and unnecessary prosecution headaches. In that sense, the new IDS size fee is doing something very American: turning organization into a competitive advantage.
Conclusion
The USPTO’s new IDS fee structure may look like a technical update buried in a broader patent-fee rule, but it has real strategic consequences. It changes how reference-heavy applications are managed, how filings are reviewed, and how prosecution teams think about disclosure. The core lesson is simple: this is no longer just a fee problem. It is a workflow problem with legal consequences.
Applicants who treat the rule as a minor surcharge will probably learn the hard way that paperwork, timing, and duplication matter. Applicants who treat it as a signal to modernize IDS practice, improve coordination, and make more deliberate disclosure decisions will be in a stronger position. In patent prosecution, the expensive part is not always the bill. Sometimes it is what the bill reveals about your process.
